Inspira Technologies has secured a second US patent approval for its VORTX orbiting blood oxygenation delivery system, a key component of the INSPIRA ART device.
This approval brings the total number of new claims for the technology to 32.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The VORTX system is designed to oxygenate blood without the use of fibre membranes, which could revolutionise the medical field by reducing blood damage and associated costs.
Traditional fibre technologies for blood oxygenation can significantly damage blood cells, as they force blood through multiple fibre layers, creating turbulence, friction, and shear forces.
The high resistance of the fibre fabric to blood flow also creates pressure differences that can lead to severe blood component damage, including haemolysis, white blood cell damage, and blood clotting.
Inspira Technologies CEO Dagi Ben-Noon said: “We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA ART.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataINSPIRA ART is designed to support the 20 million patients in intensive care units with respiratory failure every year, a majority of whom depend on mechanical ventilators.
It helps maintain stable oxygen saturation levels without requiring ventilators.
Inspira Technologies OXY received approval from the Israeli Ministry of Health for its INSPIRA ART100 system in July 2024, marking a milestone in its efforts to commercialise its medical technology.
It also received 510(k) clearance from the US Food and Drug Administration (FDA) for cardiopulmonary bypass procedures and Israeli AMAR certification for both extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures.
Inspira Technologies developed the INSPIRA ART with adaptive blood monitoring and oxygenation technology.
This system is designed to rebalance oxygen saturation levels in patients, potentially allowing them to remain awake during treatment and reducing reliance on invasive mechanical ventilation systems that necessitate intubation and medically induced coma.
